HC Wainwright & Co. Reiterates Buy on Longboard Pharmaceuticals, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Longboard Pharmaceuticals (NASDAQ:LBPH) and maintained a $60 price target.

May 07, 2024 | 2:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating and a $60 price target for Longboard Pharmaceuticals.
The reiteration of a Buy rating and a significant price target by a reputable analyst like Patrick Trucchio could instill confidence among investors and potentially drive up the stock price in the short term. The specific mention of a $60 price target suggests a strong conviction in the company's future performance, which could positively influence investor sentiment.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100